Cassava Sciences renames to Filana Therapeutics; new ticker FLNA effective March 11

FILANA THERAPEUTICS, INC.

Company changed legal name to Filana Therapeutics, Inc. effective March 10, 2026.
Common stock begins trading on Nasdaq under ticker FLNA on March 11, 2026.
New name reflects strategic focus on modulating filamin A protein for CNS disorders like TSC-related epilepsy.
Amended bylaws modernize provisions for meetings, advance notice, director terms, and uncertificated shares.
No changes to restated certificate of incorporation beyond the name change.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

FILANA THERAPEUTICS, INC.: Adopted amended and restated By-Laws reflecting the name change and clarifying provisions on stockholder and board meetings, advance notice, director terms, special meetings, inspectors of election, and uncertificated shares (effective 2026-03-10).

Change: bylaw amendment
Effective: 2026-03-10

Exact text from the filing

The Company’s board of directors also adopted amended and restated By-Laws of the Company (“Amended By-Laws”) reflecting the Name Change, effective as of March 10, 2026.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

FILANA THERAPEUTICS, INC.: Company changed its legal name to Filana Therapeutics, Inc. via amendment to Restated Certificate of Incorporation (effective 2026-03-10).

Change: charter amendment
Effective: 2026-03-10

Exact text from the filing

Effective March 10, 2026, Cassava Sciences, Inc. changed its legal name (the “Name Change”) to Filana Therapeutics, Inc. (the “Company”).

View on SEC.gov

40 governance changes filed in the last 30 days. Browse all governance changes →

FILANA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-007422

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.